{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:08:54Z","timestamp":1791950934166,"version":"4.3.4"},"reference-count":138,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R257-A14720"],"award-info":[{"award-number":["R257-A14720"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010733","name":"B\u00f8rnecancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clml.2021.07.009","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T03:18:24Z","timestamp":1626405504000},"page":"725-733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"21","author":[{"given":"Kjeld","family":"Schmiegelow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie Utke","family":"Rank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Dworkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"van der Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.07.009_bib0001","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1200\/JCO.2013.50.2708","article-title":"Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia","volume":"32","author":"Douer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0002","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.009_bib0003","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0004","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12562","article-title":"Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"96","author":"Toft","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.07.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000858","article-title":"Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion","volume":"5","author":"Burke","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.clml.2021.07.009_bib0006","doi-asserted-by":"crossref","first-page":"444","DOI":"10.12688\/f1000research.10768.1","article-title":"Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy","volume":"6","author":"Schmiegelow","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.clml.2021.07.009_bib0007","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.009_bib0008","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/ejh.12097","article-title":"Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol","volume":"90","author":"Toft","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.07.009_bib0009","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/pbc.21022","article-title":"Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia","volume":"49","author":"Steiner","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0011","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/pbc.25767","article-title":"Ammonia Levels Should Not Be Used as a Surrogate Marker of Levels of Asparaginase Activity in Acute Lymphoblastic Leukemia Patients","volume":"63","author":"Tong","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0012","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/pbc.26123","article-title":"Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation","volume":"63","author":"Kloos","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0013","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/leu.2008.165","article-title":"Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study","volume":"22","author":"Appel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.009_bib0014","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/sj.leu.2403011","article-title":"Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients","volume":"17","author":"Wang","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.009_bib0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/pbc.23041","article-title":"Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial","volume":"57","author":"Schrey","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0016","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pbc.25319","article-title":"PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol","volume":"62","author":"Henriksen","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0017","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0018","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.16495","article-title":"Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium","volume":"190","author":"Mondelaers","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.009_bib0019","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.18.02439","article-title":"Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge","volume":"37","author":"Liu","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0020","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.16254","article-title":"Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker","volume":"189","author":"Kloos","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.009_bib0021","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2020.258525","article-title":"Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia","author":"Khalil","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.009_bib0022","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0023","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/10428194.2016.1218004","article-title":"Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review","volume":"58","author":"Beaupin","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.009_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/10781552211007549","article-title":"Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions","author":"Santos","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2021.07.009_bib0025","doi-asserted-by":"crossref","first-page":"e27797","DOI":"10.1002\/pbc.27797","article-title":"Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions","volume":"66","author":"Cooper","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0026","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/clpt.2010.94","article-title":"Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity","volume":"88","author":"Chen","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2021.07.009_bib0027","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2014-03-563742","article-title":"HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies","volume":"124","author":"Fernandez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0028","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.15660","article-title":"Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008","volume":"184","author":"Hojfeldt","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.009_bib0029","doi-asserted-by":"crossref","first-page":"e27458","DOI":"10.1002\/pbc.27458","article-title":"A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia","volume":"66","author":"Kloos","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0030","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.009_bib0031","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12072-019-09971-2","article-title":"Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis","volume":"13","author":"Kamal","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.clml.2021.07.009_bib0032","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/1078155217710714","article-title":"Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature","volume":"24","author":"Blackman","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2021.07.009_bib0033","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2003-42647","article-title":"Histopathological features of L-asparaginase-induced liver disease","volume":"23","author":"Sahoo","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clml.2021.07.009_bib0034","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/cncr.28930","article-title":"Augmented Berlin-Frankfurt-Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)","volume":"120","author":"Rytting","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/leu.2016.219","article-title":"Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.009_bib0036","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1078155217701291","article-title":"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen","volume":"24","author":"Christ","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2021.07.009_bib0037","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/ejh.12600","article-title":"Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia","volume":"96","author":"Aldoss","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.07.009_bib0038","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2017.12.013","article-title":"Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses","volume":"66","author":"Burke","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.07.009_bib0039","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/10428194.2017.1349902","article-title":"PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia (dagger)","volume":"59","author":"Rausch","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.009_bib0040","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1080\/10428194.2018.1435873","article-title":"Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature","volume":"59","author":"Schulte","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.009_bib0041","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/pbc.24938","article-title":"Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial","volume":"61","author":"Plourde","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0042","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.leukres.2016.08.014","article-title":"The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance","volume":"50","author":"Horvat","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.07.009_bib0043","first-page":"75","article-title":"A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia","volume":"15","author":"Liang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clml.2021.07.009_bib0044","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0045","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0046","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2011.08588.x","article-title":"l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial","volume":"153","author":"Domenech","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.009_bib0047","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2016.7","article-title":"Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia","volume":"17","author":"Alachkar","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.clml.2021.07.009_bib0048","doi-asserted-by":"crossref","first-page":"31222","DOI":"10.1016\/S0021-9258(19)84035-8","article-title":"Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase","volume":"281","author":"Reinert","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2021.07.009_bib0049","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1472-8206.2008.00608.x","article-title":"Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies","volume":"22","author":"Labbe","year":"2008","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clml.2021.07.009_bib0050","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3109\/10428194.2013.845886","article-title":"Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors","volume":"55","author":"Al-Nawakil","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.009_bib0051","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2020.251686","article-title":"Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia","author":"Geyer","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.009_bib0052","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/oby.20426","article-title":"Racial differences in nonalcoholic fatty liver disease in the U.S. population","volume":"22","author":"Schneider","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.clml.2021.07.009_bib0053","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000353402","article-title":"L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers","volume":"59","author":"Roesmann","year":"2013","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clml.2021.07.009_bib0054","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/10428194.2019.1680839","article-title":"Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"61","author":"Derman","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.009_bib0055","article-title":"Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults","author":"Patel","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.07.009_bib0056","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood.V116.21.494.494","article-title":"PEG-Asparaginase Intensification In Adult Acute Lymphoblastic Leukemia (ALL): Significant Improvement of Outcome with Moderate Increase of Liver Toxicity In the German Multicenter Study Group for Adult ALL (GMALL) Study 07\/2003","volume":"116","author":"Goekbuget","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0057","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/10428194.2019.1658099","article-title":"Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia","volume":"61","author":"Lanvers-Kaminsky","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.009_bib0058","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.blre.2017.06.002","article-title":"Catalyzing improvements in ALL therapy with asparaginase","volume":"31","author":"Marini","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2021.07.009_bib0059","series-title":"Department of health and human services","year":"2017"},{"key":"10.1016\/j.clml.2021.07.009_bib0060","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1080\/10428194.2019.1571198","article-title":"L-carnitine does not ameliorate asparaginase-associated hepatotoxicity in a C57BL6 mouse model","volume":"60","author":"Liu","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.009_bib0061","doi-asserted-by":"crossref","first-page":"e00194","DOI":"10.14309\/crj.0000000000000194","article-title":"L-carnitine and Vitamin B Complex for PEG-L-asparaginase-Induced Hepatotoxicity","volume":"6","author":"Arora","year":"2019","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.clml.2021.07.009_bib0062","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/10428194.2019.1666379","article-title":"Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia","volume":"61","author":"Sea","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.009_bib0063","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/qjmed\/hcaa097","article-title":"Butter in blood: hypertriglyceridemia secondary to pegylated","volume":"113","author":"Singh","year":"2020","journal-title":"QJM"},{"key":"10.1016\/j.clml.2021.07.009_bib0064","article-title":"Asparaginase-Induced Hypertriglyceridemia Presenting as Pseudohyponatremia during Leukemia Treatment","volume":"2014","author":"Hinson","year":"2014","journal-title":"Case Rep Pediatr"},{"key":"10.1016\/j.clml.2021.07.009_bib0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/1078155219833438","article-title":"Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia","volume":"26","author":"Lau","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2021.07.009_bib0066","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/blood.2019002132","article-title":"How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia","volume":"135","author":"Aldoss","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0067","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s10067-015-3075-y","article-title":"High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus","volume":"34","author":"Kuroda","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clml.2021.07.009_bib0068","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.3324\/haematol.2016.160507","article-title":"Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia","volume":"102","author":"Mogensen","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.009_bib0069","first-page":"1","article-title":"Effect of Fish Oil Supplementation on Hyperlipidemia during Childhood Acute Lymphoblastic Leukemia Treatment - A Pilot Study","author":"Laumann","year":"2020","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.660627","article-title":"Case Report: The Use of Intravenous SMOFlipid Infusion to Treat Severe Asparaginase-Induced Hypertriglyceridemia in Two Pediatric Acute Lymphoblastic Leukemia Patients","volume":"9","author":"Lau","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.clml.2021.07.009_bib0071","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1590\/2359-3997000000068","article-title":"PEG-asparaginase induced severe hypertriglyceridemia","volume":"60","author":"Galindo","year":"2016","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.clml.2021.07.009_bib0072","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2006-04-015511","article-title":"Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients","volume":"108","author":"Caruso","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0073","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"Grace","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.009_bib0074","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","article-title":"Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","volume":"131","author":"Rank","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0075","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3121\/cmr.2009.866","article-title":"Virchow's contribution to the understanding of thrombosis and cellular biology","volume":"8","author":"Kumar","year":"2010","journal-title":"Clinical medicine & research"},{"key":"10.1016\/j.clml.2021.07.009_bib0076","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.3747\/co.23.3077","article-title":"Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia","volume":"23","author":"Sibai","year":"2016","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0077","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-2008-1046625","article-title":"Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report","volume":"206","author":"Korte","year":"1994","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.clml.2021.07.009_bib0078","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0079","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.ejca.2014.06.023","article-title":"Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia","volume":"50","author":"Bhojwani","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0080","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3324\/haematol.2014.109413","article-title":"The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia","volume":"99","author":"Tong","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.009_bib0081","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231209","article-title":"Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia","volume":"15","author":"Mogensen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2021.07.009_bib0082","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1160\/TH07-10-0620","article-title":"L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia","volume":"100","author":"Appel","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2021.07.009_bib0083","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2012.290","article-title":"The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia","volume":"27","author":"Truelove","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.009_bib0084","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V83.2.386.386","article-title":"Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency","volume":"83","author":"Mitchell","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0085","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/STROKEAHA.107.500124","article-title":"Changes in background blood-brain barrier integrity between lacunar and cortical ischemic stroke subtypes","volume":"39","author":"Wardlaw","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.clml.2021.07.009_bib0086","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/j.1538-7836.2010.04034.x","article-title":"Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors","volume":"8","author":"van Zaane","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clml.2021.07.009_bib0087","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2002-06-1901","article-title":"Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration","volume":"101","author":"Nowak-Gottl","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0088","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1182\/blood-2010-01-263012","article-title":"Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study","volume":"115","author":"Mitchell","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0089","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cam4.1094","article-title":"A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients","volume":"6","author":"Roininen","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2021.07.009_bib0090","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.thromres.2019.11.002","article-title":"Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia - A NOPHO ALL2008 study","volume":"184","author":"Jarvis","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.clml.2021.07.009_bib0091","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jstrokecerebrovasdis.2008.10.004","article-title":"Long-term sequelae after cerebral venous thrombosis in functionally independent patients","volume":"18","author":"Koopman","year":"2009","journal-title":"Journal of stroke and cerebrovascular diseases: the official journal of National Stroke Association"},{"key":"10.1016\/j.clml.2021.07.009_bib0092","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004561","article-title":"Long-term psychological consequences of symptomatic pulmonary embolism: a qualitative study","volume":"4","author":"Noble","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.clml.2021.07.009_bib0093","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/asheducation-2016.1.413","article-title":"The post-thrombotic syndrome","volume":"2016","author":"Kahn","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2021.07.009_bib0094","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1055\/s-0039-1679938","article-title":"PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design","volume":"119","author":"O'Brien","year":"2019","journal-title":"Thrombosis and haemostasis"},{"key":"10.1016\/j.clml.2021.07.009_bib0095","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3324\/haematol.2018.194175","article-title":"THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents","volume":"104","author":"Greiner","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.009_bib0096","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1160\/TH02-11-0283","article-title":"Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study","volume":"90","author":"Mitchell","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2021.07.009_bib0097","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2141.2006.06209.x","article-title":"Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study","volume":"134","author":"Kuhle","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.009_bib0098","first-page":"47","article-title":"Anticoagulation proteins C and S","volume":"214","author":"Esmon","year":"1987","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clml.2021.07.009_bib0099","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD013399","article-title":"Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia","author":"Utke Rank","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.clml.2021.07.009_bib0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.19.02208","article-title":"Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age","volume":"38","author":"Rank","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0101","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2015.64.5812","article-title":"Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia","volume":"34","author":"Liu","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0102","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.18.01877","article-title":"Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study","volume":"37","author":"Albertsen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0103","first-page":"371","article-title":"Calcium and adenosine triphosphate control of cellular pathology: asparaginase-induced pancreatitis elicited via protease-activated receptor 2","author":"Peng","year":"2016","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.clml.2021.07.009_bib0104","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ceca.2017.05.010","article-title":"Ca(2+) signalling underlying pancreatitis","volume":"70","author":"Gerasimenko","year":"2018","journal-title":"Cell calcium"},{"key":"10.1016\/j.clml.2021.07.009_bib0105","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3324\/haematol.2018.199356","article-title":"Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report","volume":"104","author":"Wolthers","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.009_bib0106","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0140-6736(14)60649-8","article-title":"Acute pancreatitis","volume":"386","author":"Lankisch","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.07.009_bib0107","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S1470-2045(17)30424-2","article-title":"Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study","volume":"18","author":"Wolthers","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0108","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/MCG.0000000000000827","article-title":"Risk Factors for Asparaginase-associated Pancreatitis: A Systematic Review","volume":"51","author":"Oparaji","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clml.2021.07.009_bib0109","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood.V89.6.1886","article-title":"Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia","volume":"89","author":"Parsons","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00004836-200301000-00016","article-title":"Issues in hyperlipidemic pancreatitis","volume":"36","author":"Yadav","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clml.2021.07.009_bib0111","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/pbc.22305","article-title":"Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia","volume":"54","author":"Cohen","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0112","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26559","article-title":"Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents","volume":"64","author":"Persson","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0113","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pbc.26183","article-title":"Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia","volume":"64","author":"Raja","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0114","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26891","article-title":"Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens","volume":"65","author":"Denton","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0115","doi-asserted-by":"crossref","first-page":"e27071","DOI":"10.1002\/pbc.27071","article-title":"Association between body mass index and pancreatitis in children with acute lymphoblastic leukemia","volume":"65","author":"Mogensen","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0116","doi-asserted-by":"crossref","first-page":"e27437","DOI":"10.1002\/pbc.27437","article-title":"Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia","volume":"66","author":"Wolthers","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0117","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis","volume":"53","author":"Kearney","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0118","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.2020006583","article-title":"Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia","volume":"137","author":"Gottschalk Hojfeldt","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0119","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0120","article-title":"Relapse risk following truncation of PEG-asparaginase in childhood acute lymphoblastic leukemia","author":"Gottschalk H\u00f8jfeldt","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0121","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/pbc.21721","article-title":"Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia","volume":"51","author":"Wu","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0122","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/j.clinthera.2020.02.015","article-title":"Successful Management of l-Asparaginase-Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase-Associated Pancreatitis?","volume":"42","author":"Aydin K\u00f6ker","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.clml.2021.07.009_bib0123","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1002\/phar.1460","article-title":"Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis","volume":"34","author":"Buie","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clml.2021.07.009_bib0124","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12185-017-2219-z","article-title":"Prophylactic use of octreotide for asparaginase-induced acute pancreatitis","volume":"106","author":"Sakaguchi","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2021.07.009_bib0125","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/cncr.23716","article-title":"Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic","volume":"113","author":"Morimoto","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0126","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3324\/haematol.2016.147595","article-title":"Osteonecrosis in children with acute lymphoblastic leukemia","volume":"101","author":"Kunstreich","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.009_bib0127","doi-asserted-by":"crossref","first-page":"e27300","DOI":"10.1002\/pbc.27300","article-title":"Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia","volume":"65","author":"Mogensen","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0128","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood.2020008471","article-title":"Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations","volume":"137","author":"Yang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/1535370213519215","article-title":"Pravastatin prevents steroid-induced osteonecrosis in rats by suppressing PPARgamma expression and activating Wnt signaling pathway","volume":"239","author":"Jiang","year":"2014","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.clml.2021.07.009_bib0130","article-title":"Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone treated mice","author":"Finch","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.07.009_bib0131","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.009_bib0132","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.009_bib0133","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1200\/JCO.2001.19.5.1297","volume":"19","author":"Rizzari","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0134","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood.V99.8.2734","article-title":"Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial","volume":"99","author":"Duval","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0135","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0136","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.009_bib0137","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.009_bib0138","article-title":"Relapse risk following truncation of PEG-asparaginase in childhood acute lymphoblastic leukemia","author":"Gottschalk Hojfeldt","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:39:14Z","timestamp":1761871154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":138,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2152265021002822"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}